Receptor for activated protein C kinase 1 (RACK1) is overexpressed in papillary thyroid carcinoma

Thyroid

Volumn 21, Issue 11, 2011, Pages 1217-1225

  Myklebust, Line M ^a   Akslen, Lars A ^a,b   Varhaug, Jan Erik ^a,b   Lillehaug, Johan R ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; K RAS PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; RECEPTOR FOR ACTIVATED C KINASE 1;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER RISK; CONTROLLED STUDY; DIFFERENTIATED THYROID CANCER; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; THYROID GLAND; THYROID PAPILLARY CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GTP-BINDING PROTEINS; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTORS, CELL SURFACE; THYROID NEOPLASMS; YOUNG ADULT;

EID: 83755221065     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2010.0186     Document Type: Article

References (48)

1. Davies L, Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164-2167.
2. Yu GP, Li JC, Branovan D, McCormick S, Schantz SP 2010 Thyroid cancer incidence and survival in the national cancer institute surveillance, epidemiology and end results race/ethnicity groups. Thyroid 20:465-473.
3. Ugolini C, Giannini R, Lupi C, Salvatore G, Miccoli P, Proietti A, Elisei R, Santoro M, Basolo F 2007 Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. Thyroid 17:381-388. (Pubitemid 46878840)
4. Fluge O, Bruland O, Akslen LA, Lillehaug JR, Varhaug JE 2006 Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid 16:161-175.
5. Akslen LA, LiVolsi VA 2000 Prognostic significance of his-tologic grading compared with subclassification of papillary thyroid carcinoma. Cancer 88:1902-1908. (Pubitemid 30213001)
6. Riesco-Eizaguirre G, Santisteban P 2007 New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy. Endocr Relat Cancer 14:957-977. (Pubitemid 351252429)
7. Xing MZ 2007 BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28:742-762.
8. McCahill A, Warwicker J, Bolger GB, Houslay MD, Yar-wood SJ 2002 The RACK1 scaffold protein: a dynamic cog in cell response mechanisms. Mol Pharmacol 62:1261-1273. (Pubitemid 35403822)
9. Hu L, Lu F, Wang Y, Liu Y, Liu D, Jiang Z, Wan C, Zhu B, Gan L, Wang Y, Wang Z 2006 RACK1, a novel hPER1-interacting protein. J Mol Neurosci 29:55-63. (Pubitemid 43853043)
10. Besson A, Wilson TL, Yong VW 2002 The anchoring protein RACK1 links protein kinase Cepsilon to integrin beta chains. Requirements for adhesion and motility. J Biol Chem 277:22073-22084. (Pubitemid 34952362)
11. Chang BY, Chiang M, Cartwright CA 2001 The interaction of Src and RACK1 is enhanced by activation of protein kinase C and tyrosine phosphorylation of RACK1. J Biol Chem 276:20346-20356.
12. Sklan EH, Podoly E, Soreq H 2006 RACK1 has the nerve to act: structure meets function in the nervous system. Prog Neurobiol 78:117-134. (Pubitemid 43290718)
13. Lopez-Bergami P, Habelhah H, Bhoumik A, Zhang W, Wang LH, Ronai Z 2005 RACK1 mediates activation of JNK by protein kinase C. Mol Cell 19:309-320. (Pubitemid 41074887)
14. Steele MR, McCahill A, Thompson DS, MacKenzie C, Isaacs NW, Houslay MD, Bolger GB 2001 Identification of a surface on the beta-propeller protein RACK1 that interacts with the cAMP-specific phosphodiesterase PDE4D5. Cell Signal 13:507-513. (Pubitemid 32545452)
15. Battaini F, Pascale A 2005 Protein kinase C signal trans-duction regulation in physiological and pathological aging. Ann N Y Acad Sci 1057:177-192. (Pubitemid 43211634)
16. Battaini F, Pascale A, Paoletti R, Govoni S 1997 The role of anchoring protein RACK1 in PKC activation in the ageing rat brain. Trends Neurosci 20:410-415. (Pubitemid 27364512)
17. Mamidipudi V, Cartwright CA 2009 A novel pro-apoptotic function of RACK1: suppression of Src activity in the intrinsic and Akt pathways. Oncogene 28:4421-4433.
18. Arimoto K, Fukuda H, Imajoh-Ohmi S, Saito H, Takekawa M 2008 Formation of stress granules inhibits apoptosis by suppressing stress-responsive MAPK pathways. Nat Cell Biol 10:1324-1332.
19. Kubota T, Yokosawa N, Yokota S, Fujii N 2002 Association of mumps virus V protein with RACK1 results in dissociation of STAT-1 from the alpha interferon receptor complex. J Virol 76:12676-12682. (Pubitemid 35386952)
20. Hermanto U, Zong CS, Li W, Wang LH 2002 RACK1, an insulin-like growth factor I (IGF-I) receptor-interacting protein, modulates IGF-I-dependent integrin signaling and promotes cell spreading and contact with extracellular matrix. Mol Cell Biol 22:2345-2365. (Pubitemid 34224638)
21. Chen S, Lin F, Shin ME, Wang F, Shen L, Hamm HE 2008 RACK1 regulates directional cell migration by acting on G betagamma at the interface with its effectors PLC beta and PI3K gamma. Mol Biol Cell 19:3909-3922.
22. Berns H, Humar R, Hengerer B, Kiefer FN, Battegay EJ 2000 RACK1 is up-regulated in angiogenesis and human carcinomas. FASEB J 14:2549-2558.
23. Egidy G, Jule S, Bosse P, Bernex F, Geffrotin C, Vincent-Naulleau S, Horak V, Sastre-Garau X, Panthier JJ 2008 Transcription analysis in the MeLiM swine model identifies RACK1 as a potential marker of malignancy for human melanocytic proliferation. Mol Cancer 7:34-46.
24. Nagashio R, Sato Y, Matsumoto T, Kageyama T, Satoh Y, Shinichiro R, Masuda N, Goshima N, Jiang SX, Okayasu I 2009 Expression of RACK1 is a novel biomarker in pulmonary adenocarcinomas. Lung Cancer 69:54-59.
25. Wang Z, Zhang B, Jiang L, Zeng X, Chen Y, Feng X, Guo Y, Chen Q 2008 RACK1, an excellent predictor for poor clinical outcome in oral squamous carcinoma, similar to Ki67. Eur J Cancer 45:490-496.
26. Chang BY, Conroy KB, Machleder EM, Cartwright CA 1998 RACK1, a receptor for activated C kinase and a homolog of the beta subunit of G proteins, inhibits activity of src tyro-sine kinases and growth of NIH 3T3 cells. Mol Cell Biol 18:3245-3256. (Pubitemid 28240497)
27. Mamidipudi V, Dhillon NK, Parman T, Miller LD, Lee KC, Cartwright CA 2007 RACK1 inhibits colonic cell growth by regulating Src activity at cell cycle checkpoints. Oncogene 26:2914-2924. (Pubitemid 46701439)
28. Bjorndal B, Myklebust LM, Rosendal KR, Myromslien FD, Lorens JB, Nolan G, Bruland O, Lillehaug JR 2007 RACK1 regulates Ki-Ras-mediated signaling and morphological transformation of NIH 3T3 cells. Int J Cancer 120:961-969. (Pubitemid 46214294)
29. Subauste MC, Ventura-Holman T, Du L, Subauste JS, Chan SL, Yu VC, Maher JF 2009 RACK1 downregulates levels of the pro-apoptotic protein Fem1b in apoptosis-resistant colon cancer cells. Cancer Biol Ther 8:2297-2305.
30. Mourtada-Maarabouni M, Kirkham L, Farzaneh F, Williams GT 2005 Functional expression cloning reveals a central role for the receptor for activated protein kinase C 1 (RACK1) in T cell apoptosis. J Leukoc Biol 78:503-514. (Pubitemid 41061322)
31. Zhang WZ, Cheng GZ, Gong JL, Hermanto U, Zong CS, Chan J, Cheng JQ, Wang LH 2008 RACK1 and CIS mediate the degradation of BimEL in cancer cells. J Biol Chem 283:16416-16426.
32. Chu LY, Chen YH, Chuang NN 2005 Dimerize RACK1 upon transformation with oncogenic ras. Biochem Biophys Res Commun 330:474-482.
33. Cao XX, Xu JD, Xu JW, Liu XL, Cheng YY, Wang WJ, Li QQ, Chen Q, Xu ZD, Liu XP 2009 RACK1 promotes breast carcinoma proliferation and invasion/metastasis in vitro and in vivo. Breast Cancer Res Treat 123:375-386.
34. Cao XX, Xu JD, Liu XL, Xu JW, Wang WJ, Li QQ, Chen Q, Xu ZD, Liu XP 2009 RACK1: a superior independent predictor for poor clinical outcome in breast cancer. Int J Cancer 127:1172-1179.
35. Zhang WZ, Zong CS, Hermanto U, Lopez-Bergami P, Ronai Z, Wang LH 2006 RACK1 recruits STAT3 specifically to insulin and insulin-like growth factor 1 receptors for activation, which is important for regulating anchorage- independent growth. Mol Cell Biol 26:413-424. (Pubitemid 43089756)
36. Mamidipudi V, Zhang J, Lee KC, Cartwright CA 2004 RACK1 regulates G1/S progression by suppressing Src ki-nase activity. Mol Cell Biol 24:6788-6798. (Pubitemid 38944357)
37. Liu YV, Hubbi ME, Pan F, McDonald KR, Mansharamani M, Cole RN, Liu JO, Semenza GL 2007 Calcineurin promotes hypoxia-inducible factor 1alpha expression by depho-sphorylating RACK1 and blocking RACK1 dimerization. J Biol Chem 282:37064-37073.
38. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks N, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gus-terson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JWC, Leung SY, Yuen ST, Weber BL, Siegler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA 2002 Mutations of the BRAF gene in human cancer. Nature 417:949-954. (Pubitemid 34716871)
39. Garnett MJ, Marais R 2004 Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6:313-319. (Pubitemid 39361432)
40. Schubbert S, Shannon K, Bollag G 2007 Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7:295-308. (Pubitemid 46480970)
41. Wan PTC, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R; Cancer Genome Project 2004 Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855-867.
42. Friday BB, Adjei AA 2008 Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 14:342-346. (Pubitemid 351226098)
43. Lemoine NR, Mayall ES, Wyllie FS, Farr CJ, Hughes D, Padua RA, Thurston V, Williams ED, Wynfordthomas D 1988 Activated Ras oncogenes in human thyroid cancers. Cancer Res 48:4459-4463.
44. Namba H, Rubin SA, Fagin JA 1990 Point mutations of Ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 4:1474-1479. (Pubitemid 20356608)
45. Haugen DRF, Lillehaug JR, Akslen LA 1999 Enhanced expression of EGF receptor and low frequency of ras mutations in X-ray-induced rat thyroid tumours. Virchows Arch 435:434-441. (Pubitemid 29472203)
46. Tang KT, Lee CH 2010 BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications. J Chin Med Assoc 73:113-128.
47. Mitsiades CS, Negri J, McMullan C, McMillin DW, Sozo-poulos E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Poulaki V, Batt D, Mitsiades N 2007 Targeting BRAFV600E in thyroid carcinoma: therapeutic implications. Mol Cancer Ther 6:1070-1078. (Pubitemid 46554578)
48. Liu DX, Liu Z, Condouris S, Xing MZ 2007 BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. J Clin Endocr Metab 92:2264-2271. (Pubitemid 46997132)